{
  "claim_id": "claim_005",
  "claim": "Flublok (quadrivalent) was evaluated in the pivotal trial against Fluarix (quadrivalent standard-dose vaccine).",
  "document": {
    "pdf_name": "Grohskopf_et_al.__2023_"
  },
  "extraction_result": {
    "success": true,
    "total_snippets_found": 1
  },
  "extracted_evidence": [
    {
      "id": "comp_1",
      "quote": "Children were randomized n a 2:1 ratio to receive either Flu cel vax Quad rival ent (0.5 mL/dose containing 15 \u00b5g HA per virus for all ages) or aicensed comparator egg based IIV4 (0.25 mL/dose containing 7.5 \u00b5g HA per virus for those aged 6 through 35 months and 0.5 mL/dose containing 15 \u00b5g HA per virus for those aged 36 through 47 months) (130).",
      "relevance_explanation": "This quote describes a pivotal trial in which Flu cel vax Quadrivalent was compared to a licensed comparator egg-based IIV4, but it does not mention Flublok or Fluarix. It does not support the claim about Flublok vs Fluarix, so it is not relevant.",
      "source": "completeness_check",
      "metadata": {
        "extraction_round": 2,
        "targeted_aspect": "general"
      }
    }
  ]
}